Betamethasone dipropionate ointment (augmented), 0.05% is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 13 years of age or older.
From the U.S. FDA-approved label for Betamethasone. Full label: DailyMed.
Betamethasone dipropionate ointment (augmented), 0.05% is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 13 years of age or older.
From the U.S. FDA-approved label for Betamethasone. Full label: DailyMed.
Apply a thin film of betamethasone dipropionate ointment (augmented), 0.05% to the affected skin areas once or twice daily. Therapy should be discontinued when control is achieved. If no improvement is seen within 2 weeks, reassessment of diagnosis may be necessary.
Directions from the U.S. FDA-approved label for Betamethasone — your doctor or pharmacist may advise differently.
Betamethasone dipropionate ointment (augmented), 0.05% is contraindicated in patients who are hypersensitive to betamethasone dipropionate, to other corticosteroids, or to any ingredient in this preparation., Hypersensitivity to any component of this medicine.
Excerpt from the U.S. FDA-approved label for Betamethasone. Talk to a pharmacist or doctor before use.
Effects on endocrine system: Betamethasone dipropionate ointment (augmented), 0.05% can cause reversible HPA axis suppression with the potential for glucocorticosteroid insufficiency during and after withdrawal of treatment. Risk factor(s) include the use of high-potency topical corticosteroids, use over a large surface area or to areas under occlusion, prolonged use, altered skin barrier, liver failure, and use in pediatric patients. Modify use should HPA axis suppression develop., Ophthalmic Adverse Reactions: Betamethasone dipropionate ointment (augmented), 0.05% may increase the risk of cataracts and glaucoma.
Warnings and precautions excerpt from the U.S. FDA-approved label for Betamethasone — not a complete list. Talk to a pharmacist or doctor before use.
Most common adverse reactions (<1%) are: erythema, folliculitis, pruritus, and vesiculation. To report SUSPECTED ADVERSE REACTIONS, contact Fougera Pharmaceuticals Inc. at 1-800-645-9833 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Excerpt from the U.S. FDA-approved label for Betamethasone — not a complete list. Talk to a pharmacist or doctor about side effects.
8 brands · 3 makers in the NepalDoc catalog — see the full Betamethasone guide →
What is Betalar S?
Betalar S Tablet is a Betamethasone medicine made by Lark Laboratories Ltd. It comes as Tablet.
What is Betalar S used for?
According to its FDA label, Betamethasone is used for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 13 years of age or older.
What is the generic name of Betalar S?
The generic name of Betalar S is Betamethasone.
Which brands of Betamethasone are available in Nepal?
8 brands of Betamethasone are listed in the NepalDoc catalog, from 3 makers — including Betalar Drop, Betasone 0.5mg Drop, Betnelan 0.5mg Tablet, Betnesol 0.5mg Oral Drop, Betnesol 4mg Injection, Betnesol 0.5mg Tablet.
What are the side effects of Betamethasone?
Most common adverse reactions (<1%) are: erythema, folliculitis, pruritus, and vesiculation. To report SUSPECTED ADVERSE REACTIONS, contact Fougera Pharmaceuticals Inc. at 1-800-645-9833 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
This page is information only and is not medical advice. Medicine details come from the sources listed above and may change — always confirm the medicine, strength and dose with a pharmacist or doctor before use. A catalog listing does not guarantee that a medicine is in stock at any pharmacy.
Every NepalDoc section, one tap away.
Find doctors by specialty across Nepal.
